Third Harmonic Bio Inc. (THRD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Third Harmonic Bio Inc. (THRD) has a cash flow conversion efficiency ratio of -0.049x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.48 Million) by net assets ($272.62 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Third Harmonic Bio Inc. (THRD) total market value for the company's overall valuation and market capitalisation.
Third Harmonic Bio Inc. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Third Harmonic Bio Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Third Harmonic Bio Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Third Harmonic Bio Inc. ranked by their cash flow conversion efficiency. See debt repayment capacity of Third Harmonic Bio Inc. to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Unique Optical Industrial Co Ltd
TWO:3441
|
0.045x |
|
Innoprise Plantations Bhd
KLSE:6262
|
0.075x |
|
Zhejiang Power New Energy Co. Ltd. A
SHG:688184
|
N/A |
|
Evolution Global Acquisition Corp Class A Ordinary Shares
NASDAQ:EVOX
|
0.003x |
|
ODFJELL TECHNOLOGYLTD
F:ND4
|
0.302x |
|
Jantsa Jant Sanayi ve Ticaret AS
IS:JANTS
|
0.132x |
|
Freightcar America Inc
NASDAQ:RAIL
|
0.334x |
|
XANO Industri AB (publ)
ST:XANO-B
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Third Harmonic Bio Inc. (2020–2024)
The table below shows the annual cash flow conversion efficiency of Third Harmonic Bio Inc. from 2020 to 2024. View THRD live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $285.15 Million | $-34.50 Million | -0.121x | -59.41% |
| 2023-12-31 | $269.08 Million | $-20.43 Million | -0.076x | +37.16% |
| 2022-12-31 | $289.07 Million | $-34.92 Million | -0.121x | -135.83% |
| 2021-12-31 | $-46.71 Million | $-15.75 Million | 0.337x | -32.64% |
| 2020-12-31 | $-18.36 Million | $-9.19 Million | 0.500x | -- |
About Third Harmonic Bio Inc.
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It also develops THB335, an oral small molecule KIT inhibit… Read more